Search Results

By Narjust Duma, MD, and Gilberto Lopes, MD, MBA, FAMS, FASCO  / December 10, 2019

Erlotinib Plus Ramucirumab: Ready for Prime Time?

The treatment of epidermal growth factor receptor (EGFR)-positive lung cancer changed dramatically after the results of the FLAURA trial showed improved progression-free survival with the third-generation EGFR tyrosine kinase inhibitor osimertinib as first-line therapy compared with...